A flickering-light headset for Alzheimer’s missed its main goal in a big trial. Its maker wants FDA approval anyway
Cognito Therapeutics’ Spectris, rooted in MIT research, showed no overall benefit in 673 patients. The company points to better results in people with mild disease; skeptics aren’t convinced.
An at-home headset that flickers light and clicks sound 40 times a second did not slow Alzheimer’s disease overall in its biggest test yet, its maker, Cognito Therapeutics, announced Nov. 16. The company says people with milder disease did better, and it plans to ask the Food and Drug Administration to authorize the device for them.
Outside researchers are skeptical. For now, the device, called Spectris, is not approved and is available only in studies.
What the trial found
The HOPE trial gave 673 people with mild-to-moderate Alzheimer’s either Spectris or a look-alike “sham” device for 12 months, without telling them which. On its main measure, a combined score of memory and daily function, the two groups declined about the same, according to Cognito. Nature reported that the active group declined 8.97 points and the sham group 8.82 points on that 156-point scale.
In a subgroup of 395 people with mild disease that the company had planned in advance to analyze, Spectris users declined more slowly on several measures, Cognito said:
- 56% slower decline on a standard daily-function scale (ADCS-ADL)
- 47% slower decline on the Clinical Dementia Rating–Sum of Boxes, a widely used measure of thinking and function
- no clear benefit in the 268 people with moderate disease, according to MIT’s Picower Institute
Cognito called those subgroup results “nominally” significant, meaning they weren’t adjusted for the many comparisons made. It reported no unexpected device-related side effects.
Why critics call it a failure
“The trial was negative,” Eric McDade, a neurologist at Washington University in St. Louis, told Nature. Rob Howard of University College London told the journal that if Spectris were a drug, “such a clear failure would mean that a company would not proceed to seek regulatory approval.” A smaller earlier trial of the approach also failed, Nature reported.
Cognito CEO Christian Howell said the company “had hoped to see an effect across that overall population, and we did not,” but that the mild-subgroup results bring “real hope.” He told Nature the company plans to file with the FDA next year.
How flickering light is supposed to help
Brain cells fire in rhythms called brain waves. A fast rhythm near 40 cycles per second, called gamma, is weaker in people with Alzheimer’s. In 2016, MIT neuroscientist Li-Huei Tsai’s lab reported that exposing mice to light flickering at 40 Hz for an hour a day boosted that rhythm and cut levels of amyloid, the sticky protein that builds up in Alzheimer’s brains, according to MIT. Tsai and MIT’s Ed Boyden co-founded Cambridge, Mass.-based Cognito.
Spectris looks like a pair of wraparound glasses with headphones attached. Patients wear it for an hour a day at home. Tsai called the mild-group results “strong evidence” the approach can help.
Source: Cognito Therapeutics via Business Wire, Nov. 16, 2026; Nature, Nov. 17, 2026; MIT Picower Institute, Nov. 16, 2026.